303 unknown. 303 Phase 2, 51 Phase 1, 18 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 303 | Unknown 303 |
| Phase 1 | 51 | Unknown 51 |
| Phase 3 | 18 | Unknown 18 |
Follow Stomach Diseases: new trials by email Literature Review of Stomach Diseases trials Research Report on Stomach Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis Sintilimab, Ramucirumab, SOX/XELOX - Stomach Neoplasms | Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 39 | 2024-08-01 | 2024-08-28 |
| Multimodal Rehabilitation on Gastric Adenocarcinoma Patients Following Radical D2 Gastrectomy Standard SOX/XELOX adjuvant chemotherapy plus multimodal rehabilitation - Gastric Cancer | Phase 2 | Unknown | Zhejiang Cancer Hospital | 138 | 2024-06-01 | 2024-05-17 |
| Phase II Study of Liposomal Irinotecan for Advanced Refractory Gastric Cancer Liposomal Irinotecan Hydrochloride - Gastric Cancer | Phase 2 | Unknown | Zhejiang Cancer Hospital | 50 | 2024-05-27 | 2024-05-31 |
| Neoadjuvant Adebrelimab + DOS in Locally Advanced Resectable Gastric Cancer Adebrelimab combined with DOS - Gastric Cancer | Phase 2 | Unknown | Tang-Du Hospital | 42 | 2024-05-24 | 2024-06-26 |
| Cadonilimab Plus CapeOX as First-Line Treatment for Advanced GC/GEJC With High TMEscore Cadonilimab plus CapeOX chemotherapy - Gastric Cancer | Phase 2 | Unknown | Nanfang Hospital, Southern Medical University | 50 | 2024-04-01 | 2024-03-25 |
| SOX Combined With Tislelizumab and LDRT for Neoadjuvant Treatment of Locally Advanced Gastric Cancer SOX+Tislelizumab+LDRT - Gastric Cancer | Phase 1 / Phase 2 | Unknown | West China Hospital | 64 | 2024-03-10 | 2024-02-20 |
| Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA Anlotinib, TQB2450, Albumin-Bound Paclitaxel - Gastric Cancer, Adenocarcinoma of Esophagogastric Junction | Phase 2 | Unknown | Peking University | 90 | 2024-02-25 | 2024-01-25 |
| Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression RC48 combined with Sintilimab and XELOX - Gastric Cancer | Phase 2 | Unknown | Henan Cancer Hospital | 27 | 2024-02-01 | 2024-01-26 |
| Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer Tislelizumab, Oxaliplatin, Levo-Leucovorin - Gastric Cancer | Phase 2 | Unknown | Fujian Cancer Hospital | 36 | 2024-01-01 | 2024-01-09 |
| Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients Lenvatinib and Sintilimab - Gastric Cancer | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 39 | 2023-12-01 | 2024-04-25 |
| PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors CVL218 - Advanced Solid Tumor | Phase 1 / Phase 2 | Unknown | Fujian Cancer Hospital | 96 | 2023-10-10 | 2023-10-12 |
| CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors CEA-targeted CAR-T cells - Gastric Cancer, Colon Cancer | Phase 1 / Phase 2 | Unknown | Chongqing Precision Biotech Co., Ltd | 60 | 2023-09-07 | 2024-08-09 |
| Clinical Study of Taurine Combined With Sintilimab and Chemotherapy for Treatment of Advanced Gastric Cancer Taurine, Sintilimab, XELOX regimen - Gastric Cancer | Phase 2 | Unknown | Tang-Du Hospital | 60 | 2023-08-01 | 2023-11-08 |
| Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer Tislelizumab, 5Fu, Paclitaxel injection - Gastric Cancer | Phase 2 | Unknown | Fujian Cancer Hospital | 39 | 2023-07-01 | 2023-06-22 |
| To Evaluate the Efficacy and Safety of Cadonilimab With SOX as Neoadjuvant Therapy for Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. S-1, Oxaliplatin, Cadonilimab - Gastric Cancer | Phase 2 | Unknown | Sichuan University | 37 | 2023-07-01 | 2023-07-17 |
| Efficacy and Safety of Disitamab Vedotin Combined With Sintilimab Disitamab Vedotin combined with Sintilimab - Gastric Cancer | Phase 2 | Unknown | Xiangya Hospital of Central South University | 30 | 2023-07-01 | 2023-07-05 |
| Efficacy and Safety of Fruquintinib in Combination With PD-1 Inhibitors as First-line Maintenance Therapy for Advanced HER-2 Negative Gastric Cancer: a Single-arm, Prospective, Exploratory Clinical Study Fruquintinib+PD-1 - Gastric Cancer | Phase 2 | Unknown | Wu Jun | 60 | 2023-04-01 | 2023-04-12 |
| Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer AK104, Apatinib, Paclitaxel - Gastric Cancer | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 30 | 2023-03-21 | 2023-05-10 |
| Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer PD-1 inhibitor - Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | Unknown | Sun Yat-sen University | 24 | 2023-03-09 | 2023-08-16 |
| Disitamab Vedotin Combined With Sintilimab as First-line Treatment of Elderly Patients With Gastric Cancer Disitamab Vedotin Combined With Sintilimab - Gastric Cancer | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 20 | 2023-03-01 | 2023-02-09 |
Showing 20 of 303. Sign in to see all of them.
Stomach Neoplasms (285) · Esophageal Neoplasms (18) · Pancreatic Neoplasms (14) · Colorectal Neoplasms (13) · Neoplasm Metastasis (13) · Breast Neoplasms (10) · Carcinoma, Hepatocellular (10) · Carcinoma, Non-Small-Cell Lung (10) · Colonic Neoplasms (8) · Pyloric Stenosis, Hypertrophic (7) · Adenocarcinoma Of Esophagus (6) · Carcinoma, Renal Cell (6) · Melanoma (5) · Neoplasms (5) · Biliary Tract Neoplasms (4)
Digestive System Diseases (303) · Gastrointestinal Diseases (301) · Neoplasms by Site (286) · Digestive System Neoplasms (285) · Gastrointestinal Neoplasms (283) · Neoplasms (283) · Pathological Conditions, Signs and Symptoms (30) · Neoplasms by Histologic Type (29) · Intestinal Diseases (27) · Pathologic Processes (26) · Neoplasms, Glandular and Epithelial (24) · Head and Neck Neoplasms (22) · Intestinal Neoplasms (22) · Endocrine System Diseases (21)
Oxaliplatin (55) · S 1 (combination) (40) · Capecitabine (29) · Docetaxel (26) · Paclitaxel (24) · apatinib (23) · sintilimab (23) · Cisplatin (16) · Irinotecan (15) · Fluorouracil (13) · Drug Therapy (11) · Leucovorin (11) · camrelizumab (11) · Trastuzumab (9) · Neoadjuvant Therapy (7)
Tianjin Medical University Cancer Institute and Hospital (10) · Peking University (9) · National Cancer Center, Korea (8) · National University Hospital, Singapore (8) · Chinese PLA General Hospital (7) · Fudan University (7) · Sun Yat-sen University (7) · Chinese Academy of Medical Sciences (6) · Fujian Cancer Hospital (6) · Zhejiang Cancer Hospital (6) · Hebei Medical University (5) · Nanfang Hospital, Southern Medical University (5) · Ruijin Hospital (5) · Shanghai Zhongshan Hospital (5) · The First Affiliated Hospital with Nanjing Medical University (5)
China (172) · South Korea (37) · United States (13) · Japan (8) · Singapore (8) · Taiwan (6) · France (5) · Germany (5) · United Kingdom (4) · Australia (2) · Belgium (2) · Israel (2) · Russia (2) · Brazil (1) · Colombia (1)
Wei Peng Yong, MRCP, MB ChB (4) · Se Hoon Park, MD (3) · Akira Tsuburaya (2) · Changming Huang, Professor (2) · Fuxiang Zhou, M.D. (2) · Guoxin Li, M.D., Ph.D. (2) · Kun Huei Yeh, Ph.D. (2) · Lin Yang, Ph.D. (2) · Naohito Shirai, MD., PhD (2) · Soo Chin Lee, MBBS (2) · Sook Ryun Park, M.D (2) · Wei Deng (2) · Wei Deng, M.D. (2) · Wei Xu, M.D., Ph.D. (2) · Xiangdong Cheng, MD (2)
PMID 15273542, PMID 35219300, PMID 35623069, PMID 38421211, PMID 10089184, PMID 10091726, PMID 10400410, PMID 11091234, PMID 11223832, PMID 11248153, PMID 11289756, PMID 11413430, PMID 11712875, PMID 11754382, PMID 11813623, PMID 12378346, PMID 1334988, PMID 14578723, PMID 15668283, PMID 15783049, PMID 1598671, PMID 16003309, PMID 16236737, PMID 16564913, PMID 16643334, PMID 16810012, PMID 16822992, PMID 17005947, PMID 17058319, PMID 17208639, PMID 17538089, PMID 17899453, PMID 17915803, PMID 17943760, PMID 17981197, PMID 18083691, PMID 18095269, PMID 18322744, PMID 18358585, PMID 18422971, PMID 18441328, PMID 18594925, PMID 18656040, PMID 18685899, PMID 19011538, PMID 19139439, PMID 19205735, PMID 19598150, PMID 19638912, PMID 19760315
2016 (2), 2005 (1), 2014 (1), 2018 (1)